Amid the ongoing corporatization of healthcare, activity involving special purpose acquisition companies, or SPACs, in the U.S. needs to be monitored, according to commentary published in the New England Journal of Medicine.
Though there has been scrutiny of private equity acquisitions in healthcare, “the back end of corporate acquisitions — the exit strategy — has remained largely ignored, despite arguably being more important in the long run,” wrote Nishant Uppal, MD, MBA, of Brigham and Women’s Hospital, and Zirui Song, MD, PhD, of Harvard Medical School and Massachusetts General Hospital, all in Boston.
In 2021 alone, 107 SPACs listing healthcare companies as their intended targets went public, raising a total of $23 billion, Uppal and Song noted. Read more.
